Medical Attention for Nephropathy
The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) who received a nephropathy screening or monitoring test or had evidence of nephropathy during the measurement year.
-
Group/Practice
Health Plan
Individual Clinician
Measure Info
ACP supports MIPS measure ID# 119 (NQF ID# 0062): “Diabetes: Medical Attention for Nephropathy” because the opportunity for improvement is well documented, developers cite 2018 clinical recommendations of the American Diabetes Association on “Standards of Medical Care in Diabetes” to form the basis of the measure, the numerator and denominator are well defined, the denominator includes well specified and clinically appropriate exceptions to eligibility for the measure, and measurement is repeatable and precise.